Lilly obesity meds Foundayo and Zepbound to gain CVS coverage

May 28, 2026 01:28 PM EDTUpdated 03:32 PM PharmaGLP-1 drugs Lil­ly's Foun­dayo and Zep­bound to gain CVS cov­er­age, lift­ing sales out­look Max Bayer Senior Reporter Eli Lil­ly’s flag­ship obe­si­ty med­ica­tions will be in­clud­ed in CVS Care­mark for­mu­la­ries, like­ly boost­ing sales in the most com­pet­i­tive com­mer­cial drug mar­ket. The com­pa­ny Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER